Danuglipron is a small-molecule GLP 1 agonist developed by Pfizer[1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[2]
^Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC9234956. PMID 35647711.
^Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC10203889. PMID 37213102.
danuglipron, small, molecule, agonist, developed, pfizer, that, oral, formulation, under, investigation, therapy, diabetes, mellitus, initial, results, from, randomized, controlled, trial, indicate, that, reduced, weight, improved, diabetic, control, most, com. Danuglipron is a small molecule GLP 1 agonist developed by Pfizer 1 that in an oral formulation is under investigation as a therapy for diabetes mellitus Initial results from a randomized controlled trial indicate that it reduced weight and improved diabetic control The most commonly reported adverse events were nausea diarrhea and vomiting 2 DanuglipronClinical dataOther namesPF 06882961Legal statusLegal statusInvestigationalIdentifiersIUPAC name 2 4 6 4 Cyano 2 fluorophenyl methoxy pyridin 2 yl piperidin 1 yl methyl 3 2S oxetan 2 yl methyl benzimidazole 5 carboxylic acidCAS Number2230198 02 2PubChem CID134611040UNIIDN9IUI24GPChEMBLChEMBL4518483Chemical and physical dataFormulaC 31H 30F N 5O 4Molar mass555 610 g mol 13D model JSmol Interactive imageSMILES C1CO C H 1CN2C3 C C CC C3 C O O N C2CN4CCC CC4 C5 NC CC C5 OCC6 C C C C C6 C N FInChI InChI 1S C31H30FN5O4 c32 25 14 20 16 33 4 5 23 25 19 41 30 3 1 2 26 35 30 21 8 11 36 12 9 21 18 29 34 27 7 6 22 31 38 39 15 28 27 37 29 17 24 10 13 40 24 h1 7 14 15 21 24H 8 13 17 19H2 H 38 39 t24 m0 s1Key HYBAKUMPISVZQP DEOSSOPVSA NSee also EditLotiglipron OrforglipronReferences Edit Griffith DA Edmonds DJ Fortin JP Kalgutkar AS Kuzmiski JB Loria PM et al June 2022 A Small Molecule Oral Agonist of the Human Glucagon like Peptide 1 Receptor Journal of Medicinal Chemistry 65 12 8208 8226 doi 10 1021 acs jmedchem 1c01856 PMC 9234956 PMID 35647711 Saxena AR Frias JP Brown LS Gorman DN Vasas S Tsamandouras N Birnbaum MJ May 2023 Efficacy and Safety of Oral Small Molecule Glucagon Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes A Randomized Clinical Trial JAMA Network Open 6 5 e2314493 doi 10 1001 jamanetworkopen 2023 14493 PMC 10203889 PMID 37213102 Portal nbsp Medicine nbsp This drug article relating to the gastrointestinal system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Danuglipron amp oldid 1165108843, wikipedia, wiki, book, books, library,
